VanEck Video Gaming and eSports ETF vs Recursion Pharmaceuticals Inc — how do they compare? VanEck Video Gaming and eSports ETF trades at $91.98, while Recursion Pharmaceuticals Inc trades at $3.06 (market cap $1.75B). The key difference: VanEck Video Gaming and eSports ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ESPO | RXRX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $122.30 | $6.79 |
52-Week Low | $85.25 | $2.84 |
Market Cap | — | $1.75B |
Enterprise Value | — | $1.17B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Recursion Pharmaceuticals (RXRX) trades at $3.07, down 8.08% in the last session, reflecting ongoing investor concerns about its financial performance. The stock shows a bearish technical signal with moving averages indicating selling pressure, while the company continues to report significant losses with a net income margin of -851.51% for 2025. Recent earnings have consistently beaten expectations, and analyst sentiment remains mixed with a consensus price target of $7.83 representing substantial upside potential from current levels.
The outlook for RXRX hinges on its ability to translate its AI-driven drug discovery platform into sustainable revenue growth and eventual profitability. While the company maintains analyst support and strong institutional backing, significant execution risks remain given its substantial cash burn and negative profitability metrics. The stock presents a high-risk, high-reward opportunity for investors willing to bet on the company's long-term technology potential despite current financial challenges.
Trailing returns across standard periods
ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.
Read more on ESPO →Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →